Capsyd

• 

  #1 Title

• 

  #2 Intro

• 

  #3 The Macro Problem

• 

  #4 Capsyd's Solution: Phages

• 

  #5 Phages' Strength

• 

  #6 Phages' Flaws

• 

  #7 Capsyd Technology Solution

• 

  #8 The First Target: C-Diff

• 

  #9 Challenges in Developing C-Diff Phages

• 

  #10 Capsyd's Smart Solution (Part 1)

• 

  #11 Capsyd's Smart Solution (Part 2)

• 

  #12 Pricing + Revenue

• 

  #13 Value Proposition

• 

  #14 Total Addressable Market

• 

  #15 Marketing Plan

• 

  #16 Team

• 

  #17 Contact

Capsyd is an early-stage biotech company focused on the discovery and development of phage-based antibacterial treatments.

With proprietary technology and an interdisciplinary team, we are building a library of engineered phages that addresses the current challenges in the development of phage therapeutics, the future of antibacterial treatment. Today, Capsyd's job is to develop a bioengineered phage cocktail against Clostridium difficile infections, the number one healthcare-associated infection in the United States.

For phages to be a viable therapeutic option, they need to be able to target a broad range of bacterial strains and they need to kill them immediately so bacteria won't stand a chance. Unfortunately, effective C-Diff phages with both these qualities are hard to find in nature. However, Capsyd's revolutionary tail-diversifying technology, combined with state-of-the-art machine learning-based approaches, enable us to engineer a diverse pool of closely-related phages that will target the most deadly strains of C-Diff.. and we do it with unparalleled cost-efficiency.

Our mission is to address the looming superbug crisis by bringing safe and effective antibacterials to market, with special attention to cost-efficiency, global access, and sustainability.